Ulcerative Colitis And Crohns

Question 1

Answer 1

Question 2

Answer 2

Question 3

Fill the table.

Answer 3

Question 4

Management of CD: Inducing remission and Maintenance for
(a) Mild-to-moderate CD
(b) Moderate-to-severe CD
(c) Fistulating disease.

Answer 4

Question 5

Use the statement that best fits the explanation for the statements below:
(a) Cost-effectiveness
(b) efficacy
(c) acceptability
(d) Safety
1. Azathioprine used instead of inflixamab
2. Azathoprine used instead of methotrexate.
3. Inflixmab used in isolation instead of adding DMARD
4.Budesonide selected over prednisolone.

Answer 5

1. (a) Cost-effectiveness
2. (d) Both agents have same therapeutic efficacy but azathioprine has a faster onset. Safety is the main concern with methotrexate. It is high risk drug.
3. (b) Efficacious, significantly higher rates of corticosteroid-free clinical remission and mucosal healing at week 26 among patients with active Crohn’s disease who did not have a response to first-line therapy.
4. (d) Budesonide has less systemic activity than prednisolone.

Question 6

Management of UC: Inducing remission and Maintenance for
(a) Mild UC
(b) Moderate UC
(c) Severe UC

Answer 6

Question 7

Which treatment has a fast/slow onset.

Answer 7

Question 8

What are the co-morbidities associated with treatment of UC and CD.

Question 9

MAO Azathioprine and 6-MP

Question 10

Onset of Azathioprine/6-MP

Question 11

Therapeutic effect of Aza/6-MP

Question 12

What drug increases the levels Aza/6-MP.

(A) Allopurinol
(B) Amlodipine
(C) Carbamazepine
(D) Inflixamab

Question 13

Side effects of AZA/6-MP

Question 14

Monitoring for AZA and 6-MP

Question 15

MAO of 5-ASA and what is the benefit of using 5-ASA is UC.

Question 16

When patient is on Methotrexate and they come to you telling you that they have dark urine what is it indicative of.

Question 17

MAO and administration of Infliximab, Adalimumab

Question 18

MAO of Vendolizumab

Question 19

What are the contraindications to consider with biologics

Question 20

What are the contraindications to consider with biologics

Question 21

Monitoring for biologics

Question 22

What pre-screening must you do before starting patient on AZA/6-MP.

Answer 22

TMPT screening as it metabolises AZA to its metabolite (6-MP).